TY - GEN AB - Despite incredible advances in cancer treatment in recent years, precision oncology faces many ongoing challenges in selecting the best treatment for each patient. First, we have yet to untangle the mechanisms by which many of our drugs act, especially with regards to the targets (receptors) to which they bind in the human body. To this aim we present the Cancer Targetome, which collects drug- target interactions for FDA-approved cancer drugs and proposes an evidence framework for the supporting information accompanying each drug-target interaction. AD - Oregon Health and Science University AU - Blucher, Aurora DA - 2018 DO - 10.6083/K5WJ1C DO - DOI ED - Wu, Guanming ED - McWeeney, Shannon ED - Mentor ED - Advisor ED - Mentor ID - 3132 KW - Medical Oncology KW - Neoplasms KW - cancer L1 - https://digitalcollections.ohsu.edu/record/3132/files/4096_etd.pdf L2 - https://digitalcollections.ohsu.edu/record/3132/files/4096_etd.pdf L4 - https://digitalcollections.ohsu.edu/record/3132/files/4096_etd.pdf LK - https://digitalcollections.ohsu.edu/record/3132/files/4096_etd.pdf N2 - Despite incredible advances in cancer treatment in recent years, precision oncology faces many ongoing challenges in selecting the best treatment for each patient. First, we have yet to untangle the mechanisms by which many of our drugs act, especially with regards to the targets (receptors) to which they bind in the human body. To this aim we present the Cancer Targetome, which collects drug- target interactions for FDA-approved cancer drugs and proposes an evidence framework for the supporting information accompanying each drug-target interaction. PB - Oregon Health and Science University PY - 2018 T1 - The cancer targetome and its application to a pathway perspective on targeted therapy response in acute myeloid leukemia TI - The cancer targetome and its application to a pathway perspective on targeted therapy response in acute myeloid leukemia UR - https://digitalcollections.ohsu.edu/record/3132/files/4096_etd.pdf Y1 - 2018 ER -